Dr Rayyan Hemetsberger (Medical University of Vienna, AT) led several patient-level analyses of pooled data from the BIOFLOW-II,-IV and -V trials, comparing the Orsiro DES to the Xience DES. In this interview, he presents the results of his analysis for complex vs. non-complex PCI patients. Further insights on other patient level analysis (calcified lesions, atherothrombotic risk patients) and his view on these results are disclosed.